Biogen pushes for broad CMS coverage of Alzheimer's drug — while Eli Lilly looks to escape an NCD
The nine-month quest for CMS to figure out how (or how not) to cover Biogen’s new Alzheimer’s drug Aduhelm, and potentially more amyloid-targeted monoclonal antibodies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
